RecruitingNCT05570149
EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.
EptinezuMaB in ReAl-world evidenCE: a 12-Months, Multicenter, Real-Life, Cohort Study in High-Frequency Episodic and Chronic Migraine (the EMBRACE Study)
Sponsor
IRCCS San Raffaele Roma
Enrollment
500 participants
Start Date
Jan 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria5
- Age between 18 and 75 years;
- Males and females;
- Willingness to sign the informed consent;
- High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months;
- Chronic migraine, according to the ICHD-III criteria;
Exclusion Criteria4
- Other headaches different than migraine;
- Known intolerance to eptinezumab or eccipients;
- Current treatment with other mAbs;
- Vascular disease or Raynaud.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGEptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution
migraine prophylaxis
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05570149
Related Trials
MMA Embolization for Refractory Chronic Migraine
NCT067358339 locations
Migraine Attack Pain Phase Prediction Study
NCT064596351 location
Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
NCT053424931 location
Mind Body Balance for Pediatric Migraine
NCT047156852 locations
Determining the Utility of a Behavioral Intervention in Chronic Migraine
NCT054150201 location